Skip to main content
. 2023 Feb 21;7:e2200621. doi: 10.1200/PO.22.00621

FIG A2.

FIG A2.

Comparison of (A) PD-L1 TPS and (B) TMB in stage IV KRASG12C NSCLC with and without brain metastases at diagnosis. NSCLC, non–small-cell lung cancer; PD-L1, programmed cell death ligand 1; TMB, tumor mutational burden; TPS, tumor proportion score.